Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGEN-5784 Porcine Liver with metra® ELC System in ACLF
NCT07429838Phase 2Not yet recruiting
- Sponsor
- eGenesis
- Start
- Oct 2026
- Primary completion
- Dec 2027
- Modality
- Tissue Cells
- Countries
- 1
01
Overview
A Phase 2 trial of EGEN-5784 in acute-on-chronic liver failure (ACLF), hepatic encephalopathy (HE), sponsored by eGenesis. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
EGEN-5784
03
Conditions
acute-on-chronic liver failure (ACLF)hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT07429838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07429838.